Capalbo Carlo, Belardinilli Francesca, Filetti Marco, Parisi Claudia, Petroni Marialaura, Colicchia Valeria, Tessitore Alessandra, Santoni Matteo, Coppa Anna, Giannini Giuseppe, Marchetti Paolo
Department of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy.
Medical Oncology Sant'Andrea Hospital, I-00189 Rome, Italy.
Mol Clin Oncol. 2018 Jul;9(1):30-34. doi: 10.3892/mco.2018.1634. Epub 2018 May 21.
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results in a highly effective disease control in a heavily pretreated cSCC patient.
皮肤鳞状细胞癌（cSCC）是第二常见的非黑色素瘤皮肤癌类型。基于铂类的治疗方案一直是局部晚期或转移性疾病患者姑息治疗的重要组成部分。目前尚无证据表明后续化疗方案有效，也没有靶向治疗被引入作为“标准治疗”。在此，我们报告一例老年cSCC患者，该患者对传统治疗耐药，但除每日服用姜黄素磷脂外，联合使用抗表皮生长因子受体（EGFR）药物（西妥昔单抗）成功治愈。该患者对治疗有反应，仅出现轻微的皮肤相关毒性，且11个月未复发。据我们所知，这是第一份临床证据报告，表明每日口服姜黄素磷脂的抗EGFR靶向治疗耐受性良好，且在经过大量治疗的cSCC患者中能实现高效的疾病控制。
